2 recruiting, 1 not yet recruiting. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow NK-1 receptor antagonist: new trials by email Literature Review of NK-1 receptor antagonist trials Research Report on NK-1 receptor antagonist
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1440 | 2025-05-13 | 2026-10-15 |
| A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 96 | 2025-05-13 | 2026-10-01 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Prostatic Neoplasms (1)
Chile (2) · Germany (2) · Greece (2) · Israel (2) · Italy (2) · Poland (2) · Spain (2) · Turkey (Türkiye) (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · China (1) · Colombia (1)
2025 (1)